Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kay Huebner

Showing results (11-20 of 105) with videos related to

Pageof 11
Sort By:
Cancer Science|June 29, 2011
Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibitionHidetaka Shibata, Satoshi Miuma, Joshua C Saldivar, et al.
Cytogenetic and Genome Research|February 16, 2017
Fragile Genes That Are Frequently Altered in Cancer: Players Not PassengersJenna R Karras, Morgan S Schrock, Bahadir Batar, et al.
Cellular and Molecular Life Sciences : CMLS|October 7, 2014
The FHIT gene product: tumor suppressor and genome "caretaker"Catherine E Waters, Joshua C Saldivar, Seyed Ali Hosseini, et al.
The Lancet. Oncology|December 11, 2002
FHIT: from gene discovery to cancer treatment and preventionYuri Pekarsky, Nicola Zanesi, Alexey Palamarchuk, et al.
Advances in Enzyme Regulation|November 2, 2010
Hits, Fhits and Nits: beyond enzymatic functionKay Huebner, Joshua C Saldivar, Jin Sun, et al.
Molecular Cancer|December 29, 2017
Impact of FHIT loss on the translation of cancer-associated mRNAsDaniel L Kiss, William Baez, Kay Huebner, et al.
Journal of Cellular Biochemistry|April 9, 2008
Molecular parameters of genome instability: roles of fragile genes at common fragile sitesFlavia Pichiorri, Hideshi Ishii, Hiroshi Okumura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Wwox and Ap2gamma expression levels predict tamoxifen responseGulnur Guler, Dimitrios Iliopoulos, Nilufer Guler, et al.
Genes, Chromosomes & Cancer|January 21, 2026
Endogenous Processes Underlying Clock-Like Mutational SignaturesTeresa Druck, Rami I Aqeilan, C Marcelo Aldaz, et al.
Oncotarget|December 20, 2017
The ubiquitous 'cancer mutational signature' 5 occurs specifically in cancers with deleted <i>FHIT</i> allelesStefano Volinia, Teresa Druck, Carolyn A Paisie, et al.
Pageof 11

Showing results (11-20 of 105) with videos related to

Sort By:
Pageof 11
Cancer Science|June 29, 2011
Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibitionHidetaka Shibata, Satoshi Miuma, Joshua C Saldivar, et al.
Cytogenetic and Genome Research|February 16, 2017
Fragile Genes That Are Frequently Altered in Cancer: Players Not PassengersJenna R Karras, Morgan S Schrock, Bahadir Batar, et al.
Cellular and Molecular Life Sciences : CMLS|October 7, 2014
The FHIT gene product: tumor suppressor and genome "caretaker"Catherine E Waters, Joshua C Saldivar, Seyed Ali Hosseini, et al.
The Lancet. Oncology|December 11, 2002
FHIT: from gene discovery to cancer treatment and preventionYuri Pekarsky, Nicola Zanesi, Alexey Palamarchuk, et al.
Advances in Enzyme Regulation|November 2, 2010
Hits, Fhits and Nits: beyond enzymatic functionKay Huebner, Joshua C Saldivar, Jin Sun, et al.
Molecular Cancer|December 29, 2017
Impact of FHIT loss on the translation of cancer-associated mRNAsDaniel L Kiss, William Baez, Kay Huebner, et al.
Journal of Cellular Biochemistry|April 9, 2008
Molecular parameters of genome instability: roles of fragile genes at common fragile sitesFlavia Pichiorri, Hideshi Ishii, Hiroshi Okumura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Wwox and Ap2gamma expression levels predict tamoxifen responseGulnur Guler, Dimitrios Iliopoulos, Nilufer Guler, et al.
Genes, Chromosomes & Cancer|January 21, 2026
Endogenous Processes Underlying Clock-Like Mutational SignaturesTeresa Druck, Rami I Aqeilan, C Marcelo Aldaz, et al.
Oncotarget|December 20, 2017
The ubiquitous 'cancer mutational signature' 5 occurs specifically in cancers with deleted <i>FHIT</i> allelesStefano Volinia, Teresa Druck, Carolyn A Paisie, et al.
Pageof 11